A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (NCT06079879)
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
🩺 Plain-English Summary (8th-Grade Level)
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Who can join: Review the eligibility criteria below.
Location: Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) — Glendale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (163 Sites)
Showing the first 25 of 163 sites.
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) — Glendale, Arizona
- Los Angeles Cancer Network ( Site 3491) — Glendale, California
- Stanford Cancer Institute ( Site 0107) — Stanford, California
- The Lundquist Institute ( Site 3423) — Torrance, California
- University of Colorado Anschutz Medical Campus ( Site 3425) — Aurora, Colorado
- Tufts Medical Center ( Site 3408) — Boston, Massachusetts
- University of Michigan ( Site 0008) — Ann Arbor, Michigan
- Henry Ford Hospital ( Site 3413) — Detroit, Michigan
- Optum Care Cancer Center ( Site 3497) — Las Vegas, Nevada
- Roswell Park Cancer Institute ( Site 3421) — Buffalo, New York
- Duke University Health System (DUHS) ( Site 0016) — Durham, North Carolina
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400) — Winston-Salem, North Carolina
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000) — Eugene, Oregon
- Medical University of South Carolina-Hollings Cancer Center ( Site 3426) — Charleston, South Carolina
- University of Virginia ( Site 3422) — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 3416) — Richmond, Virginia
- Hospital Universitario Austral ( Site 0104) — Pilar, Buenos Aires
- Hospital Italiano de Buenos Aires ( Site 0105) — ABB, Buenos Aires F.D.
- C.I.C.E. 9 de Julio ( Site 1001) — San Miguel de Tucumán, Tucumán Province
- Royal Prince Alfred Hospital ( Site 1100) — Camperdown, New South Wales
- Liverpool Hospital-Haematology ( Site 0501) — Liverpool, New South Wales
- Royal North Shore Hospital ( Site 0003) — St Leonards, New South Wales
- Calvary Mater Newcastle ( Site 0505) — Waratah, New South Wales
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001) — Adelaide, South Australia
- Monash Health-Haematology Research ( Site 0006) — Clayton, Victoria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Essential Thrombocythemia
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) — Glendale, Arizona
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET — Birmingham, Alabama
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance — Scottsdale, Arizona
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) — Miami, Florida
- Ruxolitinib in Thrombocythemia and Polycythemia Vera — Boston, Massachusetts
Explore by condition: All Essential Thrombocythemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.